NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

ACLX

Arcellx Inc

Jul 02 • 04:00PM ET

66.34

Dollar change +1.65
Percentage change 2.55	%

Healthcare • Biotechnology • USA • NASD

Peers: ALLO GILD CRSP NTLA FATE EDIT BLUE SGMO PSTX VCNX

| Held by: VTI IWM XBI VB VXF VBK IWO IBB VTWO SCHA

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.98	Insider Own	28.33%	Shs Outstand	55.07M	Perf Week	3.61%
Market Cap	3.66B	Forward P/E	-	EPS next Y	-3.49	Insider Trans	-1.14%	Shs Float	39.50M	Perf Month	7.12%
Enterprise Value	3.17B	PEG	-	EPS next Q	-1.02	Inst Own	86.68%	Short Float	15.80%	Perf Quarter	9.29%
Income	-162.42M	P/S	47.60	EPS this Y	-100.94%	Inst Trans	10.44%	Short Ratio	8.20	Perf Half Y	-16.11%
Sales	76.81M	P/B	8.76	EPS next Y	13.24%	ROA	-22.75%	Short Interest	6.24M	Perf YTD	-13.50%
Book/sh	7.57	P/C	6.73	EPS next 5Y	-12.70%	ROE	-35.56%	52W High	107.37 -38.21%	Perf Year	20.20%
Cash/sh	9.86	P/FCF	-	EPS past 3/5Y	-3.30% -31.14%	ROIC	-35.10%	52W Low	47.86 38.61%	Perf 3Y	255.33%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	92.27%	Volatility	3.89% 4.25%	Perf 5Y	-
Dividend TTM	-	EV/Sales	41.21	EPS Y/Y TTM	-180.15%	Oper. Margin	-248.22%	ATR (14)	2.96	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.93	Sales Y/Y TTM	-41.66%	Profit Margin	-211.46%	RSI (14)	57.44	Recom	1.11
Dividend Gr. 3/5Y	- -	Current Ratio	4.93	EPS Q/Q	-726.17%	SMA20	1.77%	Beta	0.28	Target Price	111.69
Payout	-	Debt/Eq	0.13	Sales Q/Q	-79.29%	SMA50	5.26%	Rel Volume	0.65	Prev Close	64.69
Employees	163	LT Debt/Eq	0.11	Earnings	May 08 AMC	SMA200	-8.96%	Avg Volume	761.39K	Price	66.34
IPO	Feb 04, 2022	Option/Short	Yes / Yes	EPS/Sales Surpr.	-52.58% -58.33%	Trades		Volume	507,024	Change	2.55%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-17-25	Initiated	Citigroup	Buy	$110
Oct-08-24	Initiated	Redburn Atlantic	Buy	$109
Sep-03-24	Initiated	Cantor Fitzgerald	Overweight
May-31-24	Initiated	Piper Sandler	Overweight	$70
Mar-07-24	Initiated	Morgan Stanley	Overweight	$81
Jan-04-24	Reiterated	Needham	Buy	$65 → $71
Dec-19-23	Initiated	Scotiabank	Sector Outperform	$66
Oct-30-23	Initiated	TD Cowen	Outperform
Oct-17-23	Initiated	UBS	Buy	$52
May-18-23	Initiated	Truist	Buy	$60
Apr-14-23	Initiated	Robert W. Baird	Outperform	$39
Mar-14-23	Initiated	Stifel	Buy	$43
Feb-13-23	Initiated	H.C. Wainwright	Buy	$42
Dec-13-22	Resumed	BofA Securities	Buy	$29 → $37
Oct-31-22	Initiated	Guggenheim	Buy	$36
Oct-27-22	Initiated	Needham	Buy	$31
Jul-20-22	Initiated	Canaccord Genuity	Buy	$32
Mar-01-22	Initiated	SVB Leerink	Outperform	$47
Mar-01-22	Initiated	BofA Securities	Buy	$24

Show Previous Ratings

Jun-17-25 12:57PM	Citi initiates coverage on biotech amid improving sentiment in sector (Investing.com)
06:49AM	EHA 2025: Anito-cel to disrupt CAR-T market in multiple myeloma (Clinical Trials Arena)
May-23-25 09:10AM	New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs (PR Newswire)
May-21-25 04:00PM	Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 (Business Wire) +8.26%
May-20-25 07:46AM	Baron Discovery Fund Initiated a Position in Arcellx (ACLX) (Insider Monkey)
09:30AM	Loading…
May-14-25 09:30AM	Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma (Business Wire)
May-12-25 08:25AM	Here's Why Arcellx (ACLX) Declined in Q1 (Insider Monkey)
May-08-25 05:10PM	Arcellx, Inc. (ACLX) Reports Q1 Loss, Lags Revenue Estimates (Zacks) +6.27%
04:00PM	Arcellx Provides First Quarter 2025 Financial Results and Business Highlights (Business Wire)
May-03-25 04:51AM	The Play On Legend Biotech (Seeking Alpha)
Apr-29-25 11:45AM	Baron Health Care Fund Q1 2025 Top Net Purchases And Sales (Seeking Alpha)
11:30AM	Baron Health Care Fund Q1 2025 Top Contributors And Detractors (Seeking Alpha)
Apr-27-25 02:22PM	Baron Health Care Fund Q1 2025 Shareholder Letter (Seeking Alpha)
Apr-23-25 08:49PM	Arcellx, Inc. (ACLX): Among Takeover Rumors Hedge Funds Are Buying (Insider Monkey)
Apr-11-25 04:26PM	Arcellx (ACLX): Among Billionaire Stanley Druckenmiller's Top Stock Picks with Huge Upside Potential (Insider Monkey)
03:50AM	Loading…
Mar-30-25 03:50AM	abrdn Life Sciences Investors Q4 2024 Commentary (Seeking Alpha)
Mar-20-25 04:00PM	Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors (Business Wire)
Feb-27-25 07:05PM	Arcellx, Inc. (ACLX) Reports Q4 Loss, Lags Revenue Estimates (Zacks) +5.59%
04:00PM	Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights (Business Wire)
Feb-26-25 04:00PM	Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference (Business Wire)
Feb-24-25 03:08PM	Is Arcellx, Inc. (ACLX) An Oversold Biotech Stock to Buy Now? (Insider Monkey)
Feb-19-25 10:20AM	Is Arcellx (ACLX) Poised to Capture Significant Market Share? (Insider Monkey)
Dec-27-24 02:09PM	Arcellx Stock Earns 82 Relative Strength Rating (Investor's Business Daily)
Dec-10-24 09:00PM	ASH 2024: Arcellx publishes positive results for Anito-cel in multiple myeloma (Clinical Trials Arena) +5.73%
Dec-09-24 04:22PM	Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead. (Investor's Business Daily)
07:50AM	Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients (Benzinga)
Dec-08-24 11:00PM	Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition (Business Wire)
Nov-13-24 12:00PM	Are You Looking for a Top Momentum Pick? Why Arcellx, Inc. (ACLX) is a Great Choice (Zacks)
Nov-08-24 09:40AM	Is Arcellx (ACLX) Outperforming Other Medical Stocks This Year? (Zacks)
Nov-07-24 05:15PM	Arcellx, Inc. (ACLX) Reports Q3 Loss, Lags Revenue Estimates (Zacks) +6.65%
04:00PM	Loading…
04:00PM	Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights (Business Wire)
06:41AM	Arcellx price target raised to $106 from $81 at Morgan Stanley (TipRanks)
06:27AM	Arcellx (ACLX) Stock Jumps 6.7%: Will It Continue to Soar? (Zacks)
Nov-05-24 09:00AM	Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study (Business Wire)
07:19AM	Cancer cell therapy from Arcellx, Gilead shows promise in early data (BioPharma Dive)
Oct-31-24 10:43PM	Arcellx (ACLX) Surged in Q3. Heres Why (Insider Monkey)
Aug-08-24 05:25PM	Arcellx, Inc. (ACLX) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +12.31%
04:00PM	Arcellx Provides Second Quarter 2024 Financial Results and Business Updates (Business Wire)
Aug-02-24 06:53AM	Heres Why Arcellx (ACLX) Slipped in Q2 (Insider Monkey) -5.69%
Jul-04-24 02:13PM	FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals (InvestorPlace)
Jun-29-24 03:08AM	Insider Sale: CFO Michelle Gilson Sells 12,877 Shares of Arcellx Inc (ACLX) (GuruFocus.com)
Jun-21-24 04:42PM	Arcellx Stock Earns Relative Strength Rating Upgrade (Investor's Business Daily)
May-27-24 12:32PM	7 Biotech Stocks to Put on Your Breakthrough Radar (InvestorPlace)
May-25-24 03:11AM	Insider Sale: CFO Michelle Gilson Sells Shares of Arcellx Inc (ACLX) (GuruFocus.com)
May-17-24 08:06AM	Private Equity Prowl: 3 Overlooked Stocks Primed for Buyout Bids (InvestorPlace)
May-15-24 07:21AM	Stifel Adjusts Price Target on Arcellx to $83 From $82, Maintains Buy Rating (MT Newswires)
May-14-24 08:00AM	Evercore ISI Starts Arcellx With Outperform Rating (MT Newswires)
May-10-24 01:13PM	Arcellx Inc (ACLX) Q1 2024 Earnings: Narrower Losses and Revenue Surge (GuruFocus.com) -5.67%
04:21AM	Kite and Arcellx prepare to launch Phase III multiple myeloma trial (Clinical Trials Arena)
May-09-24 10:57PM	ACLX Stock Earnings: Arcellx Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:10PM	Arcellx, Inc. (ACLX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program (Business Wire)
04:05PM	Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program (Business Wire)
04:00PM	Arcellx Provides First Quarter 2024 Financial Results (Business Wire)
06:49AM	Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine (InvestorPlace)
May-07-24 04:00PM	Arcellx to Participate in Two Upcoming Investor Conferences (Business Wire)
May-03-24 05:57PM	Arcellx Insider Sold Shares Worth $932,557, According to a Recent SEC Filing (MT Newswires)
Apr-23-24 11:26AM	Should You Be Bullish on Arcellx (ACLX)? (Insider Monkey)
Apr-04-24 04:00PM	Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference (Business Wire)
08:40AM	How Arcellx (ACLX) Stock Stands Out in a Strong Industry (Zacks)
Mar-29-24 02:57PM	Dell, Dun & Bradstreet, Diebold Nixdorf, and More Stocks See Action From Activist Investors (Barrons.com)
Mar-28-24 08:13AM	Insiders Are Dumping These 10 Healthcare Stocks (Insider Monkey)
Mar-27-24 01:50AM	Insider Sell: Arcellx Inc's Chief Medical Officer Christopher Heery Disposes of 46,815 Shares (GuruFocus.com)
Mar-20-24 04:00PM	Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference (Business Wire)
Feb-29-24 04:00PM	Arcellx to Participate at the TD Cowen 44th Annual Health Care Conference (PR Newswire)
Feb-28-24 07:30PM	Arcellx, Inc. (ACLX) Q4 Earnings and Revenues Surpass Estimates (Zacks)
04:00PM	Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights (PR Newswire)
Feb-15-24 11:57AM	The 3 Biotech Stocks That Could Make Your February Unforgettable (InvestorPlace)
Jan-16-24 01:51PM	Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market (InvestorPlace)
Dec-22-23 01:30AM	Chief Medical Officer Christopher Heery Sells 120,000 Shares of Arcellx Inc (GuruFocus.com)
Dec-15-23 05:04PM	Pharmas Frontline: 3 Stocks Driving Revolutionary Drug Development (InvestorPlace)
Dec-08-23 04:00PM	Arcellx Announces Continued Robust Long-Term Responses from Its CART-ddBCMA (anito-cel) Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at ASH (PR Newswire) -6.87%
Nov-30-23 09:37PM	3 Biotech Stocks That Could Be Multibaggers in the Making (InvestorPlace)
Nov-21-23 08:00AM	These Stocks Are Exploding In The November Stock Market Rally (Investor's Business Daily)
Nov-16-23 10:10AM	Arcellx (ACLX) Up 5% on Partnership Expansion With Gilead (Zacks)
Nov-15-23 04:05PM	Arcellx, A Top 2% Stock, Breaks Out After Inking A $285 Million Deal With Gilead (Investor's Business Daily) +5.31%
09:47AM	Arcellx Stock Surges as Gilead Adds to Stake, Expands Collaboration (Barrons.com)
09:22AM	Gilead hands Arcellx $285M to expand BCMA cell therapy deal, sparking fresh push for congested market (FierceBiotech.com)
07:16AM	Gilead expands Arcellx cancer cell therapy deal (BioPharma Dive)
06:00AM	Kite and Arcellx Announce Expansion in Strategic Partnership (Business Wire)
06:00AM	ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP (PR Newswire)
Nov-13-23 04:47PM	Arcellx Inc (ACLX) Reports Q3 2023 Financial Results and Business Updates (GuruFocus.com)
04:00PM	Arcellx Provides Third Quarter 2023 Financial Results and Business Highlights (PR Newswire)
Nov-09-23 11:14AM	There Were 181 IPOs In 2022: $1K In Either Of These Two Would Have You Up 200%+ (Benzinga)
08:30AM	Is a Surprise Coming for Arcellx (ACLX) This Earnings Season? (Zacks)
Nov-02-23 09:40AM	Are Medical Stocks Lagging Arcellx (ACLX) This Year? (Zacks) +18.55%
09:00AM	Arcellx Announces Oral Presentation for Its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 65th ASH Annual Meeting and Exposition (PR Newswire)
Oct-26-23 04:00PM	Arcellx to Participate in Two Upcoming Investor Conferences (PR Newswire)
Oct-23-23 02:50AM	7 Biotech Stocks to Get In Now Before Investors Catch On (InvestorPlace)
Oct-17-23 09:40AM	Is Arcellx (ACLX) Stock Outpacing Its Medical Peers This Year? (Zacks)
Sep-29-23 12:43PM	25 Biggest Stocks with Negative Beta (Insider Monkey)
Sep-04-23 09:55AM	Wall Street Analysts Believe Arcellx, Inc. (ACLX) Could Rally 35.56%: Here's is How to Trade (Zacks)
Sep-01-23 09:18AM	5 Biotech Stocks to Buy as New Drug Approvals Drive Industry Prospects (Zacks)
Aug-17-23 09:55AM	Does Arcellx, Inc. (ACLX) Have the Potential to Rally 39.12% as Wall Street Analysts Expect? (Zacks)
Aug-16-23 01:21PM	Gilead (GILD), Tentarix To Develop Cancer, Inflammation Therapies (Zacks)
Aug-14-23 04:00PM	Arcellx Announces Partial Clinical Hold Lifted on iMMagine-1 Phase 2 Clinical Program and Reports Second Quarter Financial Results (PR Newswire) +6.62%
Jul-31-23 07:13AM	Arcellx's (NASDAQ:ACLX) investors will be pleased with their respectable 51% return over the last year (Simply Wall St.)
Jul-25-23 02:37AM	Should You be Bullish on Arcellx (ACLX)? (Insider Monkey)
Jun-26-23 12:48PM	Gilead (GILD) Breast Cancer Drug Gets Positive CHMP Opinion (Zacks)
Jun-22-23 11:04AM	Biotech Stock Roundup: DICE Gains on LLY Buyout, MRSN Down on Update & More (Zacks)

Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Redwood City MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Patel Kavita	Director	Jun 10 '25	Option Exercise	6.66	1,500	9,990	1,500	Jun 11 05:37 PM
Patel Kavita	Director	Jun 10 '25	Sale	67.36	1,500	101,040	0	Jun 11 05:37 PM
KAVITA K PATEL	Director	Jun 10 '25	Proposed Sale	66.86	1,500	100,290		Jun 10 04:25 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	May 23 '25	Option Exercise	0.00	22,429	0	32,011	May 28 08:18 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	May 27 '25	Sale	64.14	12,235	784,777	19,776	May 28 08:18 PM
Gilson Michelle	Officer	May 27 '25	Proposed Sale	64.14	12,235	784,776		May 27 06:50 PM
Patel Kavita	Director	May 20 '25	Option Exercise	6.66	1,500	9,990	1,500	May 20 07:58 PM
Patel Kavita	Director	May 20 '25	Sale	58.43	1,500	87,645	0	May 20 07:58 PM
Patel Kavita	Director	Apr 29 '25	Option Exercise	6.66	1,500	9,990	1,500	Apr 29 06:34 PM
Patel Kavita	Director	Apr 29 '25	Sale	64.20	1,500	96,300	0	Apr 29 06:34 PM
Yoon Derek	Director	Apr 29 '25	Proposed Sale	62.02	19,470	1,207,529		Apr 29 04:53 PM
Patel Kavita	Director	Apr 08 '25	Option Exercise	6.66	1,500	9,990	1,500	Apr 08 07:31 PM
Patel Kavita	Director	Apr 08 '25	Sale	57.50	1,500	86,250	0	Apr 08 07:31 PM
Patel Kavita	Director	Mar 18 '25	Option Exercise	6.66	1,500	9,990	1,500	Mar 18 07:01 PM
Patel Kavita	Director	Mar 18 '25	Sale	71.64	1,500	107,460	0	Mar 18 07:01 PM
Elghandour Rami	SEE REMARKS	Feb 07 '25	Option Exercise	0.00	70,211	0	187,486	Feb 26 08:13 PM
Elghandour Rami	SEE REMARKS	Feb 26 '25	Sale	62.02	38,300	2,375,517	149,186	Feb 26 08:13 PM
Elghandour Rami	Officer	Feb 26 '25	Proposed Sale	62.02	38,300	2,375,517		Feb 26 08:11 PM
Patel Kavita	Director	Feb 25 '25	Option Exercise	6.66	1,500	9,990	1,500	Feb 25 07:09 PM
Patel Kavita	Director	Feb 25 '25	Sale	63.16	1,500	94,740	0	Feb 25 07:09 PM
KAVITA K PATEL	Director	Feb 25 '25	Proposed Sale	63.01	7,500	472,575		Feb 25 04:37 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Feb 07 '25	Option Exercise	0.00	22,556	0	47,641	Feb 24 08:00 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Feb 24 '25	Sale	63.79	10,155	647,773	37,486	Feb 24 08:00 PM
Heery Christopher	Officer	Feb 24 '25	Proposed Sale	63.79	10,155	647,773		Feb 24 07:57 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Feb 07 '25	Option Exercise	0.00	22,556	0	47,641	Feb 11 07:26 PM
Elghandour Rami	SEE REMARKS	Feb 07 '25	Option Exercise	0.00	70,211	0	187,486	Feb 11 07:25 PM
Patel Kavita	Director	Feb 04 '25	Option Exercise	6.66	1,500	9,990	1,500	Feb 04 09:17 PM
Patel Kavita	Director	Feb 04 '25	Sale	64.57	1,500	96,855	0	Feb 04 09:17 PM
Patel Kavita	Director	Jan 14 '25	Option Exercise	6.66	1,500	9,990	1,500	Jan 14 07:17 PM
Patel Kavita	Director	Jan 14 '25	Sale	65.87	1,500	98,801	0	Jan 14 07:17 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jan 03 '25	Option Exercise	0.00	16,519	0	38,818	Jan 10 09:38 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jan 07 '25	Sale	75.53	4,230	319,485	28,638	Jan 10 09:38 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jan 08 '25	Sale	73.69	3,553	261,831	25,085	Jan 10 09:38 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	Jan 03 '25	Option Exercise	0.00	15,339	0	38,834	Jan 10 09:36 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	Jan 07 '25	Sale	75.68	14,012	1,060,474	13,579	Jan 10 09:36 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	Jan 08 '25	Sale	73.69	3,997	294,551	9,582	Jan 10 09:36 PM
Elghandour Rami	SEE REMARKS	Jan 03 '25	Option Exercise	0.00	53,097	0	177,809	Jan 10 09:34 PM
Elghandour Rami	SEE REMARKS	Jan 07 '25	Sale	75.53	16,474	1,244,253	131,112	Jan 10 09:34 PM
Elghandour Rami	SEE REMARKS	Jan 08 '25	Sale	73.69	13,837	1,019,689	117,275	Jan 10 09:34 PM
Heery Christopher	Officer	Jan 07 '25	Proposed Sale	75.53	8,100	611,779		Jan 07 09:39 PM
Gilson Michelle	Officer	Jan 07 '25	Proposed Sale	75.53	9,100	687,308		Jan 07 09:38 PM
Elghandour Rami	Officer	Jan 07 '25	Proposed Sale	75.53	32,000	2,416,906		Jan 07 09:37 PM
MICHELLE GILSON	Officer	Jan 07 '25	Proposed Sale	75.01	9,252	693,993		Jan 07 04:25 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	Jan 03 '25	Option Exercise	0.00	15,339	0	38,834	Jan 06 09:54 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	Jan 02 '25	Option Exercise	0.00	20,495	0	23,495	Jan 06 09:54 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	Jan 03 '25	Sale	79.55	5,502	437,674	33,332	Jan 06 09:54 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	Jan 06 '25	Sale	77.17	5,102	393,705	28,230	Jan 06 09:54 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jan 03 '25	Option Exercise	0.00	16,519	0	38,818	Jan 06 09:52 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jan 02 '25	Option Exercise	0.00	13,021	0	22,299	Jan 06 09:52 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jan 03 '25	Sale	79.55	3,301	262,588	35,517	Jan 06 09:52 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jan 06 '25	Sale	77.17	3,061	236,208	32,456	Jan 06 09:52 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jan 03 '25	Option Exercise	0.00	16,519	0	38,818	Jan 06 09:52 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jan 02 '25	Option Exercise	0.00	13,021	0	22,299	Jan 06 09:52 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jan 03 '25	Sale	79.55	3,301	262,588	35,517	Jan 06 09:52 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jan 06 '25	Sale	77.17	3,061	236,208	32,456	Jan 06 09:52 PM
Elghandour Rami	SEE REMARKS	Jan 03 '25	Option Exercise	0.00	53,097	0	177,809	Jan 06 09:51 PM
Elghandour Rami	SEE REMARKS	Jan 02 '25	Option Exercise	0.00	55,459	0	124,712	Jan 06 09:51 PM
Elghandour Rami	SEE REMARKS	Jan 03 '25	Sale	79.55	14,857	1,181,846	162,952	Jan 06 09:51 PM
Elghandour Rami	SEE REMARKS	Jan 06 '25	Sale	77.17	13,776	1,063,050	149,176	Jan 06 09:51 PM
Heery Christopher	Officer	Jan 03 '25	Proposed Sale	79.55	7,000	556,837		Jan 03 08:52 PM
Gilson Michelle	Officer	Jan 03 '25	Proposed Sale	79.55	13,000	1,034,125		Jan 03 08:50 PM
Elghandour Rami	Officer	Jan 03 '25	Proposed Sale	79.55	33,000	2,625,087		Jan 03 08:47 PM
Patel Kavita	Director	Dec 24 '24	Option Exercise	6.66	1,500	9,990	1,500	Dec 26 08:42 PM
Patel Kavita	Director	Dec 24 '24	Sale	76.97	1,500	115,451	0	Dec 26 08:42 PM
Patel Kavita	Director	Dec 03 '24	Option Exercise	6.66	1,500	9,990	1,500	Dec 05 05:58 PM
Patel Kavita	Director	Dec 03 '24	Sale	91.88	1,500	137,818	0	Dec 05 05:58 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	Nov 19 '24	Option Exercise	8.66	3,000	25,980	3,000	Nov 19 06:46 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	Nov 15 '24	Sale	88.87	1,761	156,508	0	Nov 19 06:46 PM
Patel Kavita	Director	Nov 12 '24	Option Exercise	6.66	1,500	9,990	1,500	Nov 14 04:37 PM
Patel Kavita	Director	Nov 12 '24	Sale	106.33	1,500	159,495	0	Nov 14 04:37 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	Nov 08 '24	Option Exercise	8.66	7,200	62,352	14,115	Nov 12 08:31 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	Nov 08 '24	Sale	100.55	12,354	1,242,170	1,761	Nov 12 08:31 PM
Patel Kavita	Director	Nov 08 '24	Option Exercise	13.03	33,763	439,925	33,763	Nov 12 08:30 PM
Patel Kavita	Director	Nov 11 '24	Option Exercise	15.00	15,238	228,570	15,238	Nov 12 08:30 PM
Patel Kavita	Director	Nov 07 '24	Option Exercise	6.66	8,478	56,463	8,478	Nov 12 08:30 PM
Patel Kavita	Director	Nov 08 '24	Sale	104.14	33,763	3,515,941	0	Nov 12 08:30 PM
Patel Kavita	Director	Nov 11 '24	Sale	105.92	15,238	1,614,006	0	Nov 12 08:30 PM
Patel Kavita	Director	Nov 07 '24	Sale	99.30	8,478	841,861	0	Nov 12 08:30 PM
KAVITA K PATEL	Director	Nov 08 '24	Proposed Sale	99.16	45,003	4,462,497		Nov 08 04:41 PM
MICHELLE GILSON	Officer	Nov 08 '24	Proposed Sale	99.16	14,115	1,399,643		Nov 08 04:30 PM
KAVITA K PATEL	Director	Nov 07 '24	Proposed Sale	92.98	13,976	1,299,488		Nov 07 04:33 PM
Patel Kavita	Director	Oct 22 '24	Option Exercise	6.66	1,500	9,990	1,500	Oct 22 06:48 PM
Patel Kavita	Director	Oct 22 '24	Sale	89.69	1,500	134,535	0	Oct 22 06:48 PM
KAVITA K PATEL	Director	Oct 22 '24	Proposed Sale	90.28	7,500	677,100		Oct 22 04:23 PM
Patel Kavita	Director	Oct 01 '24	Option Exercise	6.66	1,500	9,990	1,500	Oct 03 04:00 PM
Patel Kavita	Director	Oct 01 '24	Sale	82.24	1,500	123,360	0	Oct 03 04:00 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	Sep 17 '24	Option Exercise	8.66	15,000	129,900	21,915	Sep 17 08:54 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	Sep 17 '24	Sale	77.73	15,000	1,165,880	6,915	Sep 17 08:54 PM
MICHELLE GILSON	Officer	Sep 17 '24	Proposed Sale	77.01	15,000	1,155,150		Sep 17 04:39 PM
Patel Kavita	Director	Sep 10 '24	Option Exercise	6.66	1,500	9,990	1,500	Sep 12 06:27 PM
Patel Kavita	Director	Sep 10 '24	Sale	74.41	1,500	111,615	0	Sep 12 06:27 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Sep 05 '24	Option Exercise	15.00	3,421	51,315	12,699	Sep 06 05:48 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Sep 05 '24	Sale	70.02	3,421	239,526	9,278	Sep 06 05:48 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Sep 03 '24	Option Exercise	13.27	27,451	364,232	36,729	Sep 03 09:33 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Sep 03 '24	Sale	67.03	27,451	1,840,053	9,278	Sep 03 09:33 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Aug 26 '24	Option Exercise	15.00	21,684	325,260	30,962	Aug 28 04:54 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Aug 26 '24	Sale	71.12	21,684	1,542,274	9,278	Aug 28 04:54 PM
CHRISTOPHER HEERY	Officer	Aug 26 '24	Proposed Sale	69.38	48,907	3,393,168		Aug 26 04:24 PM
Patel Kavita	Director	Aug 20 '24	Option Exercise	6.66	1,500	9,990	1,500	Aug 22 04:01 PM
Patel Kavita	Director	Aug 20 '24	Sale	65.88	1,500	98,820	0	Aug 22 04:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ACLX

Arcellx Inc

Upgrade your FINVIZ experience